JY231 injection for relapsed or refractory B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment, JY231, for people whose B-cell lymphoma has returned or stopped responding to previous therapies. It aims to see if JY231 can help shrink tumors or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your lymphoma cells must have a marker called CD19.
- Your lymphoma has come back after treatment (relapsed) or did not respond well to at least two prior treatments or a stem cell transplant.
- You must have at least one measurable tumor on a CT scan, and a PET scan must show activity.
- Your overall health should be good, with an ECOG score of 0 or 1 (able to do daily activities without help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called JY231 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy targets a protein called CD19 on cancer cells, helping your immune system attack them.
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
This trial tests a new treatment called JY231 for people with a type of blood cancer (B-cell leukemia) that has come back or not responded to standard treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This trial tests an experimental drug, QLS2313, for people with certain types of blood cancer (B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma) that have not gotten better with other treatments. The goal is to see if the drug is safe and works.
Hear when a new B-Non Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.